Cardiff Oncology Inc (FRA:XE7C)
€ 2.8 0.1 (3.7%) Market Cap: 150.33 Mil Enterprise Value: 95.75 Mil PE Ratio: 0 PB Ratio: 3.01 GF Score: 59/100

Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI Transcript

Jan 18, 2022 / 10:00PM GMT
Release Date Price: €5.9
Operator

Good afternoon, and welcome to the Cardiff Oncology Data Presentation Webcast. (Operator Instructions). Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website. I would now like to turn the call over to Tom Galassi of LifeSci Advisors. Please go ahead.

Thomas Galassi

Thank you, operator, and thank you all for participating in today's conference call. Before we start, I'd like to point out that the slides referenced by management on today's call will be broadcast on the webcast system or for those of you who have dialed in by phone, you can download the webcast slides from the Cardiff Oncology homepage. I'd also like to remind all listening that certain statements in this presentation are forward-looking within the meaning of the Private Litigation Reform Act of 1995 as disclosed on the slide. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements and investors should read the risk factors set forth on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot